Scholars Central

Conference abstractPublished 2 Nov 2017

Therapeutic impact of EMAP II and CD13 expression in colorectal cancer

Authors: Manal Mohamed Saber

Minia University, Egypt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Statement of the Problem: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and a major cause of cancer mortality in the world. Despite advances in CRC treatment, a greater proportion of patients, highlighting the need for new immunotherapy. Endothelial monocyte-activating polypeptide-II (EMAP-II) is a multifunctional cytokine with pro-inflammatory properties. Aminopeptidase N (CD13) is a zinc-binding protease that has a role in cancerogenesis. It is proposed that both EMAP II and CD13 are involved in tumor progression and metastasis. The purpose of this study is to develop a novel immunotherapy expressing anti-EMAP and anti-CD13 antibodies in CRC. Methodology & Theoretical Orientation: Expression of both EMAP II and CD13 was studied in CRC patients by immunohistochemistry, flow cytometry and ELISA. The antitumour effect of the anti-EMAP II and anti-CD13 antibodies was verified by therapeutic animal experiments in vivo. Findings: There was a positive correlation between CD13 and EMAP II expression in CRC with accordingly decline in CD4 and CD8 cells. Coculture of peripheral T cells with recombinant EMAP II caused a significant increase in CD13+ T cells in comparison to control (P<0.001). In an animal model, an administration of anti-EMAP II and anti-CD13 antibodies resulted in extension of the survival of the mice compared to the untreated group. Furthermore, novel immunotherapy decreased CD13+T cells and increased CD4-positive T cells, CD8-positive T cells, NK cells. Furthermore, novel immunotherapy decreased the tumour-induced apoptosis of T cells. Conclusion & Significance: This study has demonstrated a novel promising tumour immunotherapy for CRC.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectGastroenterology & Hepatology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Manal Mohamed Saber”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels